Loading clinical trials...
Loading clinical trials...
Serum 25-Hydroxyvitamin D and Neurological Disability in Multiple Sclerosis: A Cross-Sectional Study From the Mediterranean Epidemiological Frontier
Vitamin D is hypothesized to play a role in the immunopathology and progression of multiple sclerosis (MS), yet its association with neurological disability remains uncertain, particularly in North African populations.We conducted a cross-sectional study involving 369 adult MS patients across two tertiary neurology centers in Western Libya. Serum 25-hydroxyvitamin D \[25(OH)D\] levels and Expanded Disability Status Scale (EDSS) scores were collected. Pearson correlation, ANOVA, and multivariable linear regression were used to assess associations between vitamin D and disability, adjusting for age, BMI, disease duration, and physical activity. Missing data and outliers were handled systematically using validated R and Python workflows.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Faculty of medicine zintan university
Tripoli, Tripoli, Libya
Start Date
August 1, 2023
Primary Completion Date
February 15, 2025
Completion Date
April 8, 2025
Last Updated
August 19, 2025
369
ACTUAL participants
Lead Sponsor
University of Zintan
NCT06276634
NCT07225504
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06809192